Girija Raman

The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans

Kazuyoshi Toyama, Heike Wulff, K. George Chandy et al. · Journal of Clinical Investigation · 2008 · 222 citations

Medicine, Cardiology, Pharmacology +17

Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a New Activator of KCa2 and KCa3.1 Potassium Channels, Potentiates the Endothelium-Derived Hyperpolarizing Factor Response and Lowers Blood Pressure

Ananthakrishnan Sankaranarayanan, Girija Raman, Christoph Busch et al. · Molecular Pharmacology · 2008 · 212 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Renal fibrosis is attenuated by targeted disruption of K _Ca 3.1 potassium channels

Ivica Grgic, Éva Kiss, Brajesh P. Kaistha et al. · Proceedings of the National Academy of Sciences · 2009 · 153 citations · Full text

Life Sciences, Nephrology, Physiology +17

The KCa3.1 Blocker TRAM-34 Reduces Infarction and Neurological Deficit in a Rat Model of Ischemia/Reperfusion Stroke

Yi‐Je Chen, Girija Raman, Silke B. Bodendiek et al. · Journal of Cerebral Blood Flow & Metabolism · 2011 · 107 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Local Delivery of the K _Ca 3.1 Blocker, TRAM-34, Prevents Acute Angioplasty-Induced Coronary Smooth Muscle Phenotypic Modulation and Limits Stenosis

Darla L. Tharp, Brian R. Wamhoff, Heike Wulff et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2008 · 107 citations · Full text

Medicine, Cardiology, Physiology +17